Antibody–Drug Conjugate Shows Promising Activity in Patients with Advanced or Metastatic EGFR Mutation–Positive NSCLC

TOP - January 2022 Vol 15, No 1 – Online Only - Lung Cancer

Patritumab deruxtecan (HER3-DxD), an investigational antibody–drug conjugate targeting the HER3 growth factor receptor, showed promising activity in patients with locally advanced or metastatic EGFR mutation–positive non–small-cell lung cancer (NSCLC) who had received previous EGFR tyrosine kinase inhibitor (TKI) therapy, according to interim results from a phase 1 dose-escalation and dose-expansion trial. These findings were presented at the American Society of Clinical Oncology 2021 virtual annual meeting.

“HER3-DxD meets an unmet medical need. EGFR tyrosine kinase inhibitor [TKI] resistance is often difficult to treat and has diverse resistance mechanisms,” said lead investigator Pasi Jänne, MD, PhD, Scientific Director, Belfer Center for Applied Cancer Science, and Director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA. “Efficacy [of HER3-DxD] is clinically meaningful and durable. Efficacy is also observed across EGFR TKI resistance mechanisms and in those without known resistance mechanisms. Antitumor efficacy was also observed across a wide range of baseline HER3 expression.”

Study Details

The study included 57 patients with EGFR mutation–positive NSCLC who were treated with 5.6 mg/kg of HER3-DxD in dose-escalation (N = 12) and dose-expansion cohort 1 (N = 45). All patients were heavily pretreated; the median number of previous lines of therapy was 4 (range, 1-9). All patients had received previous treatment with a TKI (86% received previous osimertinib), 91% had received previous treatment with platinum-based chemotherapy, and 40% had received previous treatment with a checkpoint inhibitor. Forty-seven percent of patients had central nervous system metastasis.

The confirmed objective response rate (ORR) was 39%, and the disease control rate was 72%. Sixteen percent of patients had progressive disease and 12% were not evaluable at the time of data cutoff.

The ORR rates for patients with and without previous central nervous system metastases were 32% and 41%, respectively. Overall, durable responses were observed regardless of previous treatments or history of brain metastases. In addition, clinical responses were observed across the spectrum of baseline HER3 expression.

Cell-free (cf)DNA was collected before and after treatment with HER3-DxD and was evaluable in 40 patients. Those with cfDNA clearance at 3 or 6 weeks had an ORR of 68% compared with 19% in patients who did not clear cfDNA. Patients with cfDNA clearance also had longer progression-free survival, Dr Jänne noted.

A safety analysis of 81 patients treated at all dose levels of HER3-DxD showed manageable side effects and low rates of treatment discontinuations. The incidence of grade ≥3 treatment-emergent adverse events (TEAEs) was 64%, with the most prevalent TEAEs including a decrease in platelet and neutrophil counts, fatigue, and anemia. There were 4 (5%) cases of interstitial lung disease, none of which were grade 4 or 5 severity. Overall, 7 (9%) patients discontinued treatment due to TEAEs, which included 2 cases of fatigue and 1 each of nausea, decreased appetite, interstitial lung disease, decreased neutrophil count, pneumonitis, and upper respiratory tract infection.

“Additional studies of HER3-DxD are under way, including a phase 2 pivotal study [HERTHENA-Lung01] in locally advanced or metastatic NSCLC that progressed on treatment with TKIs and platinum-based chemotherapy, and a phase 1 study of osimertinib in combination with HER3-DxD in locally advanced or metastatic EGFR-mutated NSCLC that progressed after treatment with osimertinib and platinum-based chemotherapy,” Dr Jänne said.

Expert Commentary

Invited discussant Nicolas Girard, MD, PhD, Professor, Respiratory Medicine, Versailles Saint Quentin University, and Head of the Curie-Montsouris Thorax Institute, Paris, France, said, “A major challenge is what happens when osimertinib [EGFR] resistance develops. New drugs are being developed to combat EGFR TKI resistance, and HER3 activation is one of the known resistance mechanisms.”

“The efficacy of HER3-DxD was high in the setting of heavily pretreated patients [with EGFR resistance]. Remaining questions include the impact of previous treatment sequences on efficacy and the clinical activity in patients with intracranial metastases. The striking finding of this study is the reported activity of HER3-DxD across all reported resistance mechanisms, including EGFR-related and EGFR/MET-related. Predictive biomarkers need to be assessed,” he added.

Related Items
Sacituzumab plus Pembrolizumab Shows Encouraging Antitumor Activity in Metastatic Urothelial Cancer
Patricia Stewart
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in ASCO GU 2022 Highlights
Circulating Tumor DNA Profiling May Result in Improved Detection and Treatment of CNS Lymphoma
Patricia Stewart
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in ASH 2021 Highlights
Pembrolizumab plus Chemotherapy Prolongs Survival in Patients with Triple-Negative Breast Cancer and PD-L1 Combined Positive Score ≥10
Patricia Stewart
TOP - March 2022 Vol 15, No 2 published on March 16, 2022 in SABCS
Study Finds 1 in 6 Patients with Cancer Experience “Long-Haul” COVID-19
Patricia Stewart
TOP - March 2022 Vol 15, No 2 published on February 28, 2022 in COVID-19 & Cancer
Adagrasib Shows Promising Activity in Patients with KRASᴳ¹²ᶜ-Mutated Metastatic Colorectal Cancer
Patricia Stewart
TOP - January 2022 Vol 15, No 1 – Online Only published on January 20, 2022 in Colorectal Cancer
Abiraterone Added to Androgen-Deprivation Therapy Significantly Improves Metastasis-Free Survival in Patients with High-Risk Prostate Cancer
Patricia Stewart
TOP - January 2022 Vol 15, No 1 – Online Only published on January 20, 2022 in Prostate Cancer
Amivantamab plus Lazertinib Combo Improves Response in Osimertinib-Resistant EGFR-Positive NSCLC
Patricia Stewart
TOP - November 2021 Vol 14, No 7 published on November 10, 2021 in Lung Cancer
ALK-Targeted Therapy Appears Beneficial in Patients with Adult-Onset Neuroblastoma
Patricia Stewart
TOP - November 2021 Vol 14, No 7 published on November 10, 2021 in Neuroblastoma
Sotorasib Shows Encouraging Activity in Patients with NSCLC and KRAS p.G12C Mutation
Patricia Stewart
TOP - September 2021 Vol 14, No 5 published on September 7, 2021 in Lung Cancer
Pathogenic Germline Variants Identified in Children with Neuroblastoma
Patricia Stewart
TOP - September 2021 Vol 14, No 5 published on September 7, 2021 in Genetic Counseling
Last modified: January 21, 2022